Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Soy claims

This article was originally published in The Tan Sheet

Executive Summary

Solae Company's petition for health claims that soy protein-based foods may reduce the risk of certain types of cancer is being reviewed by FDA, the St. Louis based firm announced April 16. The petition cites 58 studies supporting the relationships, Solae says. The DuPont/Bunge joint venture is "looking forward to the agency's evaluation"...

You may also be interested in...



Soy petition withdrawal

The Solae Company is formally withdrawing from further consideration the qualified health claim petition linking soy protein consumption to prevention of cancer, the company confirms in a recent letter to the agency. "The nutrition science pertaining to the health benefits of soy protein is substantial and continues to evolve," and "serves as a catalyst for futher scientific investigation," Solae states. The firm has "closely monitored recent FDA actions with respect to certain qualified health claims. With the benefit of this information, the Solae Company respectifully reserves the option to resubmit a qualified health claim petition centering on soy protein and cancer prevention in the future." The firm also is "most appreciative of the deliberate fashion in which FDA reviewed" its petition, which it announced was under review in April 2004 (1"The Tan Sheet" April 19, 2004, In Brief)...

Global Catastrophe Or Passing Nuisance? Pharma’s Coronavirus Views

While the global health threat from the now officially named SARS-CoV-2 coronavirus has grown since the start of the quarterly earnings season in early February, even many of the companies reporting more recently do not appear overly concerned about potential business impact at this stage.

Sanofi Tries To Stop Lantus Biosimilar By Getting Supreme Court To Review PTAB, Again

Sanofi seeks to delay decision clearing path for Mylan's Lantus biosimilar; says it should be able to get rehearing based on Federal Circuit's ruling that PTAB judges were not constitutionally appointed.

Topics

UsernamePublicRestriction

Register

PS096727

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel